| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on September 26, 2007
Accepted on June 13, 2008
Endocrine Unit, and Pediatric Nephrology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA; AP-HP, Hôpital Bichat Claude Bernard, Service de Biochimie hormonale et génétique; Université Paris 7, UFR Médicale, Paris, France; Service d'Endocrinologie et Service de Médecine Infantile III et Génétique Clinique, CHU de Nancy et Faculté de Médecine, Nancy-Université / Université Henri Poincaré, Nancy, France; INSERM U561, Hôpital Saint Vincent de Paul, Université Paris 5, UFR Médicale, Paris, France
* To whom correspondence should be addressed. E-mail: hjueppner{at}partners.org.
Context: Hypoparathyroidism (HP) is characterized by low parathyroid hormone (PTH) levels, hypocalcemia and hyperphosphatemia. Heterozygous mutations in preproPTH or the calcium-sensing receptor (CaSR) cause some forms of autosomal dominant HP (AD-HP). Furthermore, homozygous mutations in glial-cell missing B (GCMB) have been implicated in autosomal recessive HP (AR-HP). In most other HP patients, however, the molecular defect remains undefined.
Objective: Determine the genetic defect in the affected members of two unrelated families with AD-HP and define the underlying disease mechanism.
Subjects: Several members affected by AD-HP were investigated. The proband in family A had low calcium detected on routine blood testing, while the proband in family B had symptomatic hypocalcemia.
Methods: Mutational analysis of preproPTH, CaSR, and GCMB was performed using PCR-amplified genomic DNA of the probands and other available members of each family. The identified GCMB mutants were characterized by Western blot analysis and luciferase reporter assay using DF-1 fibroblasts.
Results: Two novel heterozygous mutations located in the last GCMB exon (c.1389delT and c.1399delC in families A and B, respectively) were identified that both lead to frame-shifts and replacement of the putative transactivation domain within carboxyl-terminal regions by unrelated amino acid sequence. The mutant GCMB proteins were well expressed and both showed dose-dependent inhibition of the transactivation capacity of wild-type protein in luciferase reporter assays.
Conclusions: The dominant negative effect observed in vitro for both GCMB mutations provides a plausible explanation for the impaired PTH secretion observed in the two unrelated families with AD-HP.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |